HBx mutations emerged during antiviral therapy: a new face of a multifaceted HBV protein?

[1]  Jiming Zhang,et al.  An antiviral drug-resistant mutant of hepatitis B virus with high replication capacity in association with a large in-frame deletion in the preS1 region of viral surface gene , 2020, Virus Genes.

[2]  Kwang-Huei Lin,et al.  Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression , 2020, Hepatology International.

[3]  Haitao Guo,et al.  Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine‐resistant HBV isolate , 2019, Antiviral research.

[4]  B. Slagle,et al.  Role of HBx in hepatitis B virus persistence and its therapeutic implications. , 2018, Current opinion in virology.

[5]  Fares Alahdab,et al.  Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis , 2016, Hepatology.

[6]  Diarmaid Hughes,et al.  Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms , 2015, Nature Reviews Genetics.

[7]  K. Borroto-Esoda,et al.  Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. , 2007, Journal of hepatology.

[8]  Angeline Bartholomeusz,et al.  Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.

[9]  R. Schinazi,et al.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. , 2001, The Journal of clinical investigation.